Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells |
Brands | Activase (Genentech Inc)
|
Categories | Thrombolytic Agents
|
Packagers | G h
|
Synonyms | t-PA t-plasminogen activator Tissue-type plasminogen activator precursor tPA
|
indication
For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
pharmacology
Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.
mechanism of action
Alteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
drug interactions
Ginkgo biloba: Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
Nitroglycerin: IV nitroglycerin may decrease the effect of alteplase.
Ticlopidine: Increased bleeding risk. Monitor for signs of bleeding.